Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.

Reinisch, Walter; Panés, Julián; Khurana, Sunil; Toth, Gabor; Hua, Fei; M Comer, Gail; Hinz, Michelle; Page, Karen; O'Toole, Margot; McDonnell Moorehead, Tara; Zhu, Hua; Sun, YanHui; Cataldi, Fabio

doi:10.1136/gutjnl-2014-308337

Public

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.

Shared by NobleBlocks on Jun 1, 2015 • 12:00 AM UTC

Authors:

Walter Reinisch

Julián Panés

Sunil Khurana

Abstract

OBJECTIVE: Interleukin 13 (IL-13) is thought to play a key role as an effector cytokine in UC. Anrukinzumab, a humanised antibody that inhibits human IL-13, was evaluated for the treatment of UC. DESIGN: In a multicentre, randomised, double-blind, placebo-controlled study, patients with active UC (M...

Subject

INTERLEUKINS

ULCERATIVE COLITIS

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!